-transparent.png){kind=logo}
Is to study the efficacy of treatment of exacerbation of chronic tubotympanic purulent otitis media with Otofa drug with the active substance Rifamycin. METHODS Performed a retrospective analysis of 37 medical histories of patients who applied to the otorhinolaryngology clinic with a diagnosis of exacerbation of chronic purulent tubotympanic otitis media in the period from January 2019 to December 2019. RESULTS Noted relief of symptoms such as throbbing noise and pain in patients receiving the topical Otofa drug (active ingredient Rifamycin) by the 3th day of therapy. Otofa also reduced otorrhea by the 5th day of therapy. CONCLUSIONS The study showed the high clinical efficacy of Otofa ear drops containing the Rifamycin antibiotic.
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
January 2023,
Vestnik otorinolaringologii,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
January 2003,
Vestnik otorinolaringologii,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
August 1947,
Archives of otolaryngology,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
December 1947,
The Medical world,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
January 2011,
Vestnik otorinolaringologii,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
December 1951,
Laval medical,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
June 1953,
Medical bulletin of the U. S. Army, Europe. United States. Army, Europe. Medical Division,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
January 2002,
Vestnik otorinolaringologii,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
January 1998,
Harefuah,
S A Karpishchenko, and
O N Sopko, and
A N Bervinova
September 1970,
Wiener medizinische Wochenschrift (1946),
